CERT - Certara, Inc. News

Barclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5

Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the

seekingalpha.com

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

marketbeat.com

Certara Q2 Earnings Call Highlights

Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as

zacks.com

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensu

Transcript: Certara Q2 2026 Earnings Conference Call

Certara (NASDAQ:CERT) reported second-quarter financial results on Tuesday. The transcript from the

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday'

Certara Lowers FY2026 Adj EPS Guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 Est; Lowers FY2026 S

Certara (NASDAQ:CERT) lowers FY2026 Adj EPS guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 analys

Certara Q2 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $93.271M Miss $98.392M Estimate

Certara (NASDAQ:CERT) reported quarterly earnings of $0.08 per share which missed the analyst consen

Certara Reports Second Quarter 2026 Financial Results

Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CER

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pi

/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CER

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CER

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in mode

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CER

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Consumer Tech News (July 6-10): Micron Plans $250B US Expansion, Apple Signs $30B Broadcom Deal & Mo

Apple partners with Broadcom on a multiyear agreement exceeding $30 billion to develop custom silico

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CER

NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CER

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives

NVIDIA Corp. (NASDAQ:NVDA) expanded its presence in life sciences AI through separate initiatives wi

Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives

Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entr

Certara Partners With NVIDIA To Advance Its Open Integrated AI Platform, Unifying Scientific Softwar

Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, is partnering with

Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in mode

Franklin Covey Cuts Revenue Forecast, Joins Ouster And Other Big Stocks Moving Lower In Thursday’s P

US stock futures mixed, Franklin Covey Co drops 19.7% after lowering revenue guidance. Other stocks

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CER

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CER

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Enc

Bragar Eagel and Squire, P. C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims

Craig-Hallum Maintains Hold on Certara, Lowers Price Target to $8

Craig-Hallum analyst Matthew Hewitt maintains Certara (NASDAQ:CERT) with a Hold and lowers the pr

BMO Capital Maintains Market Perform on Certara, Lowers Price Target to $6

BMO Capital analyst Sean Dodge maintains Certara (NASDAQ:CERT) with a Market Perform and lowers t

Barclays Maintains Equal-Weight on Certara, Lowers Price Target to $6.5

Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers the

Stephens & Co. Maintains Overweight on Certara, Lowers Price Target to $9

Stephens & Co. analyst Jeff Garro maintains Certara (NASDAQ:CERT) with a Overweight and lower

Morgan Stanley Maintains Equal-Weight on Certara, Lowers Price Target to $10

Morgan Stanley analyst Sean Laaman maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers

Baird Maintains Neutral on Certara, Lowers Price Target to $6

Baird analyst Joe Vruwink maintains Certara (NASDAQ:CERT) with a Neutral and lowers the price tar

12 Health Care Stocks Moving In Monday's Intraday Session

S&P 500 Tops 7,400 As Copper Hits Record Highs: Stock Market Today

Small caps lead a mixed Wall Street session as Trump rejects Iran's peace response, sending crud

12 Health Care Stocks Moving In Monday's Pre-Market Session

Earnings Scheduled For May 11, 2026

Certara Lowers FY2026 Adj EPS Guidance from $0.44-$0.48 to $0.35-$0.41 vs $0.45 Est; Lowers FY2026 S

Certara (NASDAQ:CERT) lowers FY2026 Adj EPS guidance from $0.44-$0.48 to $0.35-$0.41 vs $0.45 analys

Certara Q1 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $106.900M Beat $106.095M Estimate

Certara (NASDAQ:CERT) reported quarterly earnings of $0.09 per share which missed the analyst consen

Altasciences And Certara Announce Strategic Partnership To Accelerate Early-Phase Development Progra

Altasciences, a fully integrated drug development solution company, andCertara (NASDAQ:CERT), a glob

Certara Strategic Business Divestiture Comes At Right Time, Says Analyst

Certara stock rises after $135 million divestiture to Veristat as analysts weigh MIDD focus and impr

Keybanc Maintains Overweight on Certara, Lowers Price Target to $8

Keybanc analyst Brandon Nispel maintains Certara (NASDAQ:CERT) with a Overweight and lowers the p

Forecasting The Future: 7 Analyst Projections For Certara

Barclays Downgrades Certara to Equal-Weight, Maintains Price Target to $8

Barclays analyst Luke Sergott downgrades Certara (NASDAQ:CERT) from Overweight to Equal-Weight an

Barclays Maintains Overweight on Certara, Lowers Price Target to $8

Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the pr

Earnings Breakdown: Certara Q4

Certara Q4 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $103.600M Beat $103.193M Estimate

Certara (NASDAQ:CERT) reported quarterly earnings of $0.09 per share which missed the analyst consen

Earnings Scheduled For February 26, 2026

Earnings Scheduled For November 6, 2025